Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Thalidomide and its derivatives, lenalidomide and pomalidomide (also known as IMiDs), have significantly changed the treatment landscape of multiple myeloma, and the recent discovery of cereblon (CRBN) as their direct biological target has led to a deeper understanding of their complex mechanism of...

Full description

Bibliographic Details
Main Authors: Konstantinos Dimopoulos, Alexandra Søgaard Helbo, Helga Fibiger Munch‐Petersen, Lene Sjö, Jesper Christensen, Lasse Sommer Kristensen, Fazila Asmar, Niels Emil Ulrich Hermansen, Casey O'Connel, Peter Gimsing, Gangning Liang, Kirsten Grønbæk
Format: Article
Language:English
Published: Wiley 2018-02-01
Series:Molecular Oncology
Subjects:
5‐azacytidine
cereblon
epigenetics
immunomodulatory drugs
multiple myeloma
Online Access:https://doi.org/10.1002/1878-0261.12157

Internet

https://doi.org/10.1002/1878-0261.12157

Similar Items